How Advanced are Cancer Immuno-Nanotherapeutics? A Comprehensive Review of the Literature.
cancer therapy
combination therapy
engineered nanomaterials
nanotechnology
nanotoxicity
synergistic therapy
Journal
International journal of nanomedicine
ISSN: 1178-2013
Titre abrégé: Int J Nanomedicine
Pays: New Zealand
ID NLM: 101263847
Informations de publication
Date de publication:
2023
2023
Historique:
received:
01
09
2022
accepted:
14
12
2022
entrez:
13
1
2023
pubmed:
14
1
2023
medline:
17
1
2023
Statut:
epublish
Résumé
Cancer is a broad term for a group of diseases involving uncontrolled cell growth and proliferation. There is no cure for cancer despite recent significant improvements in screening, treatment, and prevention approaches. Among the available treatments, immunotherapy has been successful in targeting and killing cancer cells by stimulating or enhancing the body's immune system. Antibody-based immunotherapeutic agents that block immune checkpoint proteins expressed by cancer cells have shown promising results. The rapid development of nanotechnology has contributed to improving the effectiveness and reducing the adverse effects of these anti-cancer immunotherapeutic agents. Recently, engineered nanomaterials have been the focus of many state-of-The-art approaches toward effective cancer treatment. In this review, the contribution of various nanomaterials such as polymeric nanoparticles, dendrimers, microspheres, and carbon nanomaterials in improving the efficiency of anti-cancer immunotherapy is discussed as well as nanostructures applied to combination cancer immunotherapy.
Identifiants
pubmed: 36636642
doi: 10.2147/IJN.S388349
pii: 388349
pmc: PMC9830082
doi:
Substances chimiques
Antineoplastic Agents
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
35-48Informations de copyright
© 2023 Yadav et al.
Déclaration de conflit d'intérêts
The authors report no conflicts of interest in this work.
Références
Proc Natl Acad Sci U S A. 2020 Jun 16;117(24):13428-13436
pubmed: 32493746
Blood. 1997 Apr 15;89(8):2994-8
pubmed: 9108420
Front Immunol. 2020 Jul 07;11:1412
pubmed: 32733469
JAMA Oncol. 2019 Dec 1;5(12):1749-1768
pubmed: 31560378
Int J Nanomedicine. 2012;7:5901-14
pubmed: 23226696
Expert Opin Biol Ther. 2004 Jan;4(1):35-51
pubmed: 14680467
Biomolecules. 2021 Mar 05;11(3):
pubmed: 33807771
Sci Transl Med. 2018 Dec 12;10(471):
pubmed: 30541787
Arch Immunol Ther Exp (Warsz). 1997;45(2-3):141-7
pubmed: 9597079
J Mater Chem B. 2014 Jul 14;2(26):4055-4066
pubmed: 32261736
Nat Rev Clin Oncol. 2022 Apr;19(4):254-267
pubmed: 35082367
Int J Mol Med. 2016 Mar;37(3):690-702
pubmed: 26782731
Front Pharmacol. 2015 Dec 01;6:286
pubmed: 26648870
J Nanobiotechnology. 2018 Sep 19;16(1):71
pubmed: 30231877
Int J Nanomedicine. 2021 Feb 25;16:1525-1551
pubmed: 33658782
Gut. 2018 Feb;67(2):320-332
pubmed: 27797936
Nano Converg. 2022 Apr 28;9(1):19
pubmed: 35482149
Front Oncol. 2017 Jun 26;7:136
pubmed: 28695111
Sci Rep. 2021 Feb 15;11(1):3824
pubmed: 33589661
Colloids Surf B Biointerfaces. 2017 Dec 1;160:254-264
pubmed: 28942160
Nano Lett. 2016 Sep 14;16(9):5503-13
pubmed: 27525587
Drug Discov Today. 2020 Dec;25(12):2227-2244
pubmed: 33011342
Sci Rep. 2018 Feb 13;8(1):2907
pubmed: 29440698
Artif Cells Nanomed Biotechnol. 2018 Mar;46(2):274-283
pubmed: 28423924
Biomater Sci. 2019 Jan 29;7(2):596-606
pubmed: 30062347
Endocr Metab Immune Disord Drug Targets. 2022;22(2):212-224
pubmed: 33902424
Cancers (Basel). 2021 Dec 01;13(23):
pubmed: 34885176
Cell Mol Immunol. 2022 Jan;19(1):33-45
pubmed: 34417572
Cancer Gene Ther. 2021 Sep;28(9):911-923
pubmed: 33558704
Adv Healthc Mater. 2021 May;10(9):e2002104
pubmed: 33709564
Int J Pharm. 2021 May 15;601:120571
pubmed: 33812967
Ther Deliv. 2020 Oct;11(10):613-635
pubmed: 32933425
CA Cancer J Clin. 2020 Jan;70(1):7-30
pubmed: 31912902
Toxicol Appl Pharmacol. 2020 Sep 15;403:115139
pubmed: 32687837
Nanomedicine (Lond). 2013 Sep;8(9):1509-28
pubmed: 23914966
J Mater Chem B. 2013 Dec 28;1(48):
pubmed: 24392221
Molecules. 2020 Sep 16;25(18):
pubmed: 32947799
Front Pharmacol. 2017 May 16;8:261
pubmed: 28559844
Sci Transl Med. 2018 Feb 21;10(429):
pubmed: 29467299
Cancer Immunol Res. 2015 May;3(5):436-43
pubmed: 25941355
ACS Nano. 2022 May 24;16(5):8472-8483
pubmed: 35466668
Emergent Mater. 2022;5(6):1593-1615
pubmed: 35005431
Redox Biol. 2019 Jul;25:101174
pubmed: 30917934
J Pharmacol Exp Ther. 2019 Sep;370(3):570-580
pubmed: 30837281
Front Pharmacol. 2014 Apr 25;5:77
pubmed: 24795633
Nat Rev Cancer. 2005 Dec;5(12):965-76
pubmed: 16294217
Cancer Gene Ther. 2004 Oct;11(10):643-64
pubmed: 15286681
Nat Nanotechnol. 2017 Sep;12(9):877-882
pubmed: 28650437
J Immunother Cancer. 2021 Jul;9(7):
pubmed: 34230112
Curr Pharm Des. 2020;26(38):4909-4916
pubmed: 32851952
NAR Cancer. 2020 Feb 17;2(1):zcaa002
pubmed: 34316682
Front Immunol. 2013 May 16;4:114
pubmed: 23720661
J Hematol Oncol. 2019 Aug 28;12(1):86
pubmed: 31462327
Nature. 2004 Nov 18;432(7015):294-7
pubmed: 15549090
Nat Rev Mater. 2021;6(9):766-783
pubmed: 34026278
J Drug Deliv. 2013;2013:340315
pubmed: 23936656
Front Bioeng Biotechnol. 2021 Sep 09;9:705886
pubmed: 34568298
Front Pharmacol. 2019 Mar 11;9:1401
pubmed: 30914959
Pharmacol Rep. 2012;64(5):1020-37
pubmed: 23238461
Oncotarget. 2017 Mar 28;8(13):20741-20750
pubmed: 28186964
Nanoscale Res Lett. 2014 May 21;9(1):247
pubmed: 24994950
J Nanobiotechnology. 2022 May 28;20(1):245
pubmed: 35643505
Sci Adv. 2020 Apr 29;6(18):eaaz6579
pubmed: 32494680
ACS Nano. 2018 Jun 26;12(6):5121-5129
pubmed: 29771487
Front Chem. 2020 Oct 30;8:598160
pubmed: 33195107
Int J Nanomedicine. 2021 Aug 05;16:5281-5299
pubmed: 34385817
Br J Cancer. 2019 Jan;120(1):16-25
pubmed: 30413826
Front Immunol. 2020 May 20;11:945
pubmed: 32508829
Chem Soc Rev. 2020 Jul 6;49(13):4234-4253
pubmed: 32452475
Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2015 Sep-Oct;7(5):691-707
pubmed: 25683687
Oncotarget. 2017 Mar 28;8(13):20558-20571
pubmed: 28423552
Mol Ther. 2022 Oct 5;30(10):3133-3154
pubmed: 35405312
Biomaterials. 2022 Jun;285:121550
pubmed: 35533439
Int J Mol Sci. 2018 Oct 20;19(10):
pubmed: 30347840
Int J Pharm. 2017 Aug 7;528(1-2):675-691
pubmed: 28629982
Front Immunol. 2018 Feb 20;9:230
pubmed: 29515571
Cell. 2018 Aug 9;174(4):1031-1032
pubmed: 30096300
Annu Rev Immunol. 2022 Apr 26;40:169-193
pubmed: 35044794
Nat Commun. 2022 Jan 10;13(1):42
pubmed: 35013211
Biomater Res. 2019 Nov 21;23:20
pubmed: 31832232
Biomaterials. 2020 Feb 29;242:119926
pubmed: 32169771
Curr Drug Metab. 2020;21(14):1144-1151
pubmed: 33234100
J Colloid Interface Sci. 2022 Jun 15;616:189-200
pubmed: 35203032
Biomaterials. 2022 Mar;282:121425
pubmed: 35217344
Nat Rev Cancer. 2012 Mar 22;12(4):252-64
pubmed: 22437870
Nano Converg. 2019 Jul 15;6(1):23
pubmed: 31304563
Nat Commun. 2016 Oct 21;7:13193
pubmed: 27767031
Biomedicines. 2021 Sep 24;9(10):
pubmed: 34680425
AAPS PharmSciTech. 2014 Aug;15(4):862-71
pubmed: 24700296
Biomolecules. 2020 Dec 16;10(12):
pubmed: 33339083
J Immunother Cancer. 2019 Aug 14;7(1):220
pubmed: 31412934
Adv Healthc Mater. 2021 Mar;10(5):e2000845
pubmed: 32790039
Front Pharmacol. 2021 Feb 03;12:601626
pubmed: 33613290
Adv Mater. 2020 Apr;32(13):e1901081
pubmed: 31222852
J Immunother Cancer. 2017 Oct 17;5(1):79
pubmed: 29037250
Mater Sci Eng C Mater Biol Appl. 2016 Mar;60:569-578
pubmed: 26706565
Cancer Gene Ther. 2006 Sep;13(9):819-29
pubmed: 16424918
Trends Cancer. 2020 Apr;6(4):288-298
pubmed: 32209444
Biomedicines. 2022 Jan 21;10(2):
pubmed: 35203442
Molecules. 2019 Mar 07;24(5):
pubmed: 30866424
Semin Cancer Biol. 2022 Nov;86(Pt 2):909-922
pubmed: 35181474
Immunotargets Ther. 2012 Oct 1;2012(1):7-12
pubmed: 24791250
Mol Ther Nucleic Acids. 2015 Sep 15;4:e252
pubmed: 26372022
Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2020 Mar;12(2):e1590
pubmed: 31696664
Med Oncol. 2022 Jun 18;39(9):131
pubmed: 35716327
Int J Nanomedicine. 2015 Feb 02;10:975-99
pubmed: 25678787